Scientists Discover a New Signaling Pathway and Design a Novel Drug for Liver Fibrosis
April 25, 2024
Scientists from the University of California San Diego discovered a novel signaling pathway in liver cells, leading to a treatment for fibrosis.
Your search for “Fatty liver disease” returned 65 results
Diet Plays Critical Role in NASH Progressing to Liver Cancer in Mouse Model
June 1, 2021
Researchers at University of California San Diego School of Medicine found in a mouse model that when fed a Western diet rich in calories, fat and cholesterol, the mice progressively became obese, diabetic and developed NASH, which progressed to HCC, chronic kidney and cardiovascular disease.
Researchers Illuminate Key Role of NOX Proteins in Liver Disease
July 29, 2015
Researchers at the University of California, San Diego School of Medicine have demonstrated a direct connection between two signaling proteins and liver fibrosis, a scarring process underlying chronic liver disease, the 12th leading cause of death in the United States.
Birth Weight is Risk Factor for Fatty Liver Disease in Children
April 4, 2017
…low and high birth weights in developing Non Alcoholic Fatty Liver Disease (NAFLD), a chronic disease that often leads to a need for organ transplantation.
Too Much of a Good Thing May Lead to Too Much of a Liver As Well
February 24, 2020
UC San Diego researchers suggest that prolonged exposure to a pair of antioxidant proteins may contribute to enlargement of the liver and fatty liver diseases.
Pediatric Liver Disease Increases Risk of Developing Type 2 Diabetes
June 13, 2022
UC San Diego researchers describe connection between pediatric liver disease and increased risk of developing type 2 diabetes. Both rates are rising in children.
To Ward off Fatty Liver, Breast is Best for Mom
November 1, 2018
…or more are at lower risk for developing non-alcoholic fatty liver disease (NAFLD) years later during mid-life. With no other current prevention options aside from a healthy lifestyle, they say the finding may represent an early modifiable risk factor for a serious and chronic disease.
UC San Diego Partners with Janssen to Research New Approaches to Treat Metabolic Diseases
June 15, 2017
University of California San Diego School of Medicine has entered a five-year strategic partnership with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover meaningful treatments for metabolic diseases.
MRI Technology Quantifies Liver Response in Nonalcoholic Steatohepatitis Patients
August 19, 2016
Researchers at the University of California San Diego School of Medicine have found that a form of magnetic resonance imaging (MRI) that non-invasively measures fat density in the liver corresponds with histological (microscopic tissue analyses) responses in patients with nonalcoholic steatohepatitis (NASH).
Technique May Identify Patients with Fast-Progressing Fibrosis in Nonalcoholic Fatty Liver Disease
October 11, 2016
Combining multiple non-invasive measures, researchers at University of California San Diego School of Medicine describe a novel method to quantify the progression of nonalcoholic fatty liver disease (NAFLD) to its more dangerous and deadly states — advanced fibrosis and cirrhosis.
